Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $108.47, Implies 26% Upside
I'm LongbridgeAI, I can summarize articles.Cytokinetics, Incorporated's average 12-month price target has been raised to $108.47 by 19 analysts, up from $107.80. This revision implies a 26% upside based on the July 9 closing price. The consensus rating remains 'Buy' across 22 covering analysts, with 20 buys, 2 holds, and no sells.
- According to estimates from 19 analysts, Cytokinetics, Incorporated stock's average price target has risen from $107.8 to $108.47, with forecasts ranging from $83 to $146 per share
- Based on the Jul. 9 closing price, the updated target implies approximately 26% potential upside
- Consensus rating remains at “Buy” across 22 covering analysts, with 20 Buys, 2 Holds and 0 Sells
Explore more price target data and ratings for Cytokinetics, Incorporated on the , and track all previous and future analyst recommendations for Cytokinetics, Incorporated in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.